Invivyd Reports $41.4 Million Net Loss in Q1 2026, Revenue Increases to $13.7 Million

Invivyd, Inc. reported a net loss of $41.4 million for the first quarter of 2026, a significant increase from the $16.3 million loss recorded in the same period of 2025. The company's total revenue for the quarter was $13.7 million, up from $11.3 million year-over-year, primarily driven by increased sales of its monoclonal antibody product, PEMGARDA, which received emergency use authorization from the FDA in March 2024. The cost of product revenue rose to $1.0 million from $0.8 million, reflecting the higher sales volume.

Operating expenses surged to $56.9 million in Q1 2026, compared to $28.2 million in Q1 2025. This increase was largely attributed to a substantial rise in research and development costs, which jumped to $30.7 million from $10.6 million. The increase in R&D expenses was primarily due to heightened spending on the VYD2311 program, which saw costs escalate by $21.3 million as the company advanced its clinical trials. Selling, general, and administrative expenses also rose to $25.1 million from $16.8 million, reflecting increased personnel costs and professional fees.

As of March 31, 2026, Invivyd's total assets were reported at $241.7 million, down from $276.9 million at the end of 2025. The company had cash and cash equivalents of $184.2 million, a decrease from $226.7 million at the end of the previous fiscal year. The decline in cash reserves was attributed to ongoing operational losses and increased expenditures related to clinical trials and product development. The company also noted a substantial accumulated deficit of $995.9 million.

Strategically, Invivyd has made significant advancements in its product pipeline, including the nomination of VYD2311 as a next-generation mAb candidate for COVID-19 and the initiation of clinical trials for both VYD2311 and VBY329, a candidate for RSV. The company is also progressing with VMS063, a measles mAb candidate, and has plans for further clinical trials in pediatric populations. However, the company expressed substantial doubt about its ability to continue as a going concern without additional funding, as it may not have sufficient cash to meet its operational needs beyond one year.

Looking ahead, Invivyd aims to secure additional funding through various means, including revenue from product sales, equity offerings, and potential collaborations. The company is focused on advancing its clinical programs and expanding its product offerings to address serious viral infectious diseases. The management remains optimistic about the potential market opportunities for its products, particularly as it continues to navigate the complexities of drug development and regulatory approval processes.